Table 1 COVID-19 clinical trials with ruxolitinib and interferon alpha.

From: COVID-19 and myeloproliferative neoplasms: some considerations

  National Clinical Trial Number (NCT) Sponsor/collaborator Study design Regimen dose duration Patients Primary endpoints Phase Status
Ruxolitinib NCT04414098 Novartis Pharmaceuticals (Clinica Zabala, Argentina) OL 5-mg BID for 14 days Hospitalized, laboratory-confirmed, ARDS % of patients with clinical worsening (defined by a requirement of FIO2 > 50% and/or mechanical respiratory assistance), time frame 14 days Phase 2 Not yet recruiting
  NCT04331665 University Health Network, Toronto, Canada SA/OL 10-mg BID for 14 days, followed by 5-mg BID for 2 days, and 5-mg QD for 1 day Hospitalized, laboratory-confirmed, pneumonia % of patients with clinical worsening (defined by a requirement of FIO2 > 60% and/or mechanical respiratory assistance), time frame 6 months N/A Not yet recruiting
  NCT04348071 University of Colorado, Denver, CO, USA SA/OL 10-mg BID for 14 days Hospitalized, laboratory-confirmed, pneumonia Clinical status as assessed on eight-point scale at day 15 Phase 2, Phase 3 Not yet recruiting
  NCT04377620 Incyte Corporation (Multi-center) R/DB 5 and 15-mg BID for 28 days Hospitalized, laboratory-confirmed, ARDS 28-day mortality rate Phase 3 Recruiting
  NCT04477993 University of Sao Paulo General Hospital, Sao Paulo, Brazil R/DB 5-mg BID for 14 days Hospitalized, laboratory-confirmed, ARDS A composite outcome of death or ICU admission or mechanical ventilation at day 14 Phase 2, Phase 3 Recruiting
  NCT04362137 Novartis Pharmaceuticals/ Incyte Corporation (Multi-center) R/DB 5-mg BID for 14 days, can be extended up to 28 days Hospitalized, laboratory-confirmed, ARDS A composite outcome of death or ICU admission or mechanical ventilation, time frame 29 days Phase 3 Recruiting
  NCT04359290 Philipps University Marburg Medical Center, Marburg, Germany SA/OL 10-mg BID at day 1, dose escalation up to 15-mg BID at day 2-28 Hospitalized, laboratory-confirmed, ARDS Overall survival, time frame 28 days Phase 2 Recruiting
  NCT04334044 Grupo Cooperativo de Hemopatías Malignas, Hospital Angeles Lomas, Huixquilucan, Mexico SA/OL 5-mg BID for 14 days Laboratory-confirmed, ARDS Recovery of pneumonia, time frame 14 days Phase 1, Phase 2 Recruiting
  NCT04338958 University of Jena, Jena, Germany NR/SA/OL 10-mg BID, dose escalation up to 20-mg BID for 7 days Hospitalized, laboratory-confirmed, severe pneumonia Overall response as assessed on 25% reduction in baseline hyperinflammation score (CIS), time frame 7 days Phase 2 Recruiting
  NCT04403243 Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Russia R/OL 5-mg BID for 10 days Laboratory-confirmed, pneumonia Change from baseline as assessed on clinical assessment score (CAS) at day 12 Phase 2 Recruiting
IFNalpha NCT04320238 Shanghai Jiao Tong University School of Medicine, Shanghai, China NR/OL Interferon α1β nasal drops, 2–3 drops for each nostril per time, QID Formally serving medical staff, not directly in contact with COVID-19 patients Number of new cases, time frame 6 weeks Phase 3 Recruiting
  NCT04293887 Tongji Hospital, Wuhan, Hubei, China R/OL Interferon α1β 10 µg per nebulizer BID Laboratory-confirmed, pneumonia, symptoms onset <7 days Incidence of side effects as assessed on development of dyspnea, SPO2 ≤ 94%, respiratory rate ≥24 breaths/min, time frame 14 days Phase 1 Not yet recruiting
  1. The below list excludes observational studies, expanded access, withdrawn studies, and studies that investigate multiple experimental drugs in the same arm.
  2. NR nonrandomized, R randomized, SA single arm, OL open label, SB single blind, DB double blind, QD once a day, BID twice daily, QID four times a day.